Isomorphic Labs, a Google-backed AI company, is set to begin human trials for cancer drugs designed by AI, raising both hope ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

AI models have just taken a startling step toward autonomy. In a shocking experiment, OpenAI’s o3 model rewrote its own code ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Glenmark’s progress with a cancer treatment shows the potential of Indian pharma to move from generics to drug discovery. With tech-enabled therapies evolving fast, new inflection points spell a ...

Below are the most-read DIGITIMES Asia stories from July 7 to July 13, 2025. This week's top three highlights include China’s ...

Bill Gates has warned that AI will replace many jobs, but says coding will stay a fully human profession, even hundreds of ...

The biotechnology sector is hailing a major milestone as Isomorphic Labs, a startup incubated by Google DeepMind, prepares to enter human trials with a drug candidate designed using artificial ...

Google DeepMind subsidiary, Isomorphic Labs, has said it is ready to conduct human trials for drugs developed using its AlphaFold AI technology.

Isomorphic Labs is preparing to test AI-designed drugs in humans, marking a new phase in drug development with artificial ...

Alphabet’s AI-powered drug discovery company, Isomorphic Labs, is preparing to take its first major leap into the real world.

The oncology drug created by Isomorphic Labs using Google DeepMind’s AlphaFold 3 tool could be pivotal for cancer treatment.